The future of AAV research is promising, with ongoing efforts to improve vector design, enhance tissue specificity, and reduce immune responses. Advances in CRISPR technology and other gene-editing tools are also being integrated with AAV vectors to create more precise and effective therapies. Continued epidemiological studies will be essential in understanding the long-term effects and optimizing the use of AAVs in clinical settings.
